GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Blueprint Medicines Corp (STU:2L9) » Definitions » Gross Profit

Blueprint Medicines (STU:2L9) Gross Profit : €453.2 Mil (TTM As of Dec. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Blueprint Medicines Gross Profit?

Blueprint Medicines's gross profit for the three months ended in Dec. 2024 was €132.7 Mil. Blueprint Medicines's gross profit for the trailing twelve months (TTM) ended in Dec. 2024 was €453.2 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Blueprint Medicines's gross profit for the three months ended in Dec. 2024 was €132.7 Mil. Blueprint Medicines's Revenue for the three months ended in Dec. 2024 was €139.8 Mil. Therefore, Blueprint Medicines's Gross Margin % for the quarter that ended in Dec. 2024 was 94.91%.

Blueprint Medicines had a gross margin of 94.91% for the quarter that ended in Dec. 2024 => Durable competitive advantage

During the past 12 years, the highest Gross Margin % of Blueprint Medicines was 99.95%. The lowest was 90.04%. And the median was 96.04%.


Blueprint Medicines Gross Profit Historical Data

The historical data trend for Blueprint Medicines's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Blueprint Medicines Gross Profit Chart

Blueprint Medicines Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only 652.10 143.50 175.80 220.85 466.67

Blueprint Medicines Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 65.75 85.49 121.29 113.75 132.67

Competitive Comparison of Blueprint Medicines's Gross Profit

For the Biotechnology subindustry, Blueprint Medicines's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Blueprint Medicines's Gross Profit Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Blueprint Medicines's Gross Profit distribution charts can be found below:

* The bar in red indicates where Blueprint Medicines's Gross Profit falls into.



Blueprint Medicines Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Blueprint Medicines's Gross Profit for the fiscal year that ended in Dec. 2024 is calculated as

Gross Profit (A: Dec. 2024 )=Revenue - Cost of Goods Sold
=485.927 - 19.256
=466.7

Blueprint Medicines's Gross Profit for the quarter that ended in Dec. 2024 is calculated as

Gross Profit (Q: Dec. 2024 )=Revenue - Cost of Goods Sold
=139.78 - 7.112
=132.7

Gross Profit for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €453.2 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

Blueprint Medicines's Gross Margin % for the quarter that ended in Dec. 2024 is calculated as

Gross Margin % (Q: Dec. 2024 )=Gross Profit (Q: Dec. 2024 ) / Revenue (Q: Dec. 2024 )
=(Revenue - Cost of Goods Sold) / Revenue
=132.7 / 139.78
=94.91 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Blueprint Medicines  (STU:2L9) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Blueprint Medicines had a gross margin of 94.91% for the quarter that ended in Dec. 2024 => Durable competitive advantage


Blueprint Medicines Gross Profit Related Terms

Thank you for viewing the detailed overview of Blueprint Medicines's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Blueprint Medicines Business Description

Traded in Other Exchanges
Address
45 Sidney Street, Cambridge, MA, USA, 02139
Blueprint Medicines Corp is a biopharmaceutical company. It is developing medicines in the following focus areas; allergy, inflammation, oncology, and hematology. Its approved medicines, including Avyakit and Avyakyt, are given to patients living with systemic mastocytosis (SM) and PDGFRA Exon 18 mutant GIST in the U.S. and Europe. The company also has various other drug candidates in its pipeline such as BLU-808, BLU-222, BLU-956, and others that are being developed to treat mast cell diseases including SM and chronic urticaria, breast cancer, and other solid tumors. Geographically, it operates in the United States, which is its key revenue market, and Europe.

Blueprint Medicines Headlines

No Headlines